11.36 USD
▼-0.51-4.30%
盘后 11.53 +1.50%
2026-09-15
市值
$1.61B
市盈率
—
EPS
-3.34
股息率
—
52 周区间
7.95 – 28.25
成交量
3.99M
Beta
1.82
目标价
24.00
52W 低 7.9552W 高 28.25
价格走势
公司简介
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;...